ASCO 2025 | Finding an optimal treatment duration for immunotherapy in melanoma

So I think, you know, we’re very much whilst we’ve reduced the duration, did we reduce it the right amount? You know, so it’s the real basics that we don’t yet have a handle on. We went for 12 months because that was acceptable to patients. Six months would have been a step too far. But actually, might six months have been enough? So there’s still that gap. The other thing is that the treatment landscape is constantly evolving. So we had patients on single agent pembrolizumab and nivolumab. We then did an amendment so that we could include patients on nivolumab and ipilimumab. Now we’ve got nivolumab and relatlimab, which has come through as well. Is it going to be the same for each of those regimens? I suspect there are going to be differences. So we need to work out how we’re going to apply it to those other treatments as well. Then we’ve got new things coming through. You know, actually, could you combine this duration question with things like a cancer vaccine and immunotherapy? Where’s CAR-T going to sit in treatment? You know, so there’s so much research to continue to keep doing. Yeah. Thank you.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.